All News
Who will win? Elbow Knee, Joint Service Joint Service, or reigning champs Neutrophil Nets! Join us at Knowledge Bowl! @RheumNow #ACR19 https://t.co/IcUN4la4vP
Dr. Rachel Tate uptoTate ( View Tweet)
DAAs for Tx of hep C are changing the landscape of mixed cryo- incidence w/HCV steadily decreasing. Abstr#1723 @RheumNow @LCalabreseDO #cleclinicrheum #ACR19 https://t.co/QHDEjxPN7c
Cassandra Calabrese CCalabreseDO ( View Tweet)
Beautiful phase 2 data on a combined uricase and tolerigenic nanoparticle to reduce reactions and maintain irate lowering efficacy over 28 days. Roll on the HTH phase 3 with pegloticase #ACR19 @RheumNow #gout Abs 1235 https://t.co/NnMMgnbPbH
Philip Robinson philipcrobinson ( View Tweet)
Primary CNS vasculitis is hard to diagnose up front & bx data limited, but maybe reactive astrocytes (being CNS cells) might help differentiate versus mimics? We’ll take all the markers we can get
@ClevelandClinic @ChanmiLee @LCalabreseDO @RulaHajjAliMD #ACR19 ABST1717 @RheumNow https://t.co/gF7ayDO6vQ
David Liew drdavidliew ( View Tweet)
CZP improves PRO and most importantly sleep in non radio graphic SPAnpatients @RheumNow #ACR19 https://t.co/HfLor8jhSD
Dr. Arthur Lau ArthurRheum ( View Tweet)
#ACR19 @rheumnow Abstr#L09:
NORD-STAR trial: DMARD vs biologic 1st line Rx for early RA
All got MTX 25mg/wk x1 month then randomized to pred 20mg/taper to 5mg/d in 9 wks v. SSZ 2g bid v. HCQ 35 mg/wk + joint injx v. CZP v. TCZ v. ABT
High remiss in all group (best w/ABT)
k dao KDAO2011 ( View Tweet)
#ACR19 #rheumtwitter
@hausmannMD has a great e-poster this morning on #pedsrheum parental social media use ➡️ Over 700 parents were surveyed, can you guess how many were NOT using social media?
@rheumnow @RobShmerling @carrainc @TamarPedsRheum @DrTinyTree https://t.co/SIIpKd5HP8
Elizabeth Graef SituationRheum ( View Tweet)
Looks like giving methotrexate with pegloticase means most can complete their infusion course in uncontrolled #gout. Reduced reactions. MTX to the rescue! #ACR19 @RheumNow Abs 1236 https://t.co/UVE1ov2fno
Philip Robinson philipcrobinson ( View Tweet)
Checkpoint inhibitors in RA pts: it doesn’t matter why they flare (withdrawal of DMARD etc) - it’s manageable. Don’t deny RA patients potentially life-saving cancer immunotherapy!
@sandigursky #ACR19 ABST1339 @RheumNow following @cappelliMD’s call to arms https://t.co/oemBmibcvB
David Liew drdavidliew ( View Tweet)
#ACR19 @rheumnow ABS1481 Corrona PsA/SpA Registy: real-world use of Apremilast +biologics happens mostly in pts who received prior biologic therapy & pts not able to achieve MDA. otherwise similar characteristics vs those initiating biologic monotherapy and biologic + csDMARDs
Olga Petryna DrPetryna ( View Tweet)
NEW Guidelines for the Management of Takayasu Arteritis at #ACR19 (in one table!)
1. Everyone should get steroid sparing tx
2. Rec TNF > TCZ
3. Monitor pts closely!
4. Don't treat asymptomatic CRP
5. Med mgmt > surgical mgmt
Overall agreed - what about role of MTX?
@RheumNow https://t.co/vzpBHRDcKI
Mike Putman EBRheum ( View Tweet)
Do you feel comfortable combining apremilast with biologics in refractory/difficult to treat PsA patients ?
Olga Petryna DrPetryna ( View Tweet)
MMF potentially reduces serum levels of estrogen and progestin. Theoretically could reduce the efficacy of hormonal contraception. Consider IUDs and implants. #ACR19 @rheumnow #lupus
Maeve Gamble MaeveGamble ( View Tweet)
#RheumaTwitter celebrity @DrJuanOvalles is in the house! It was so wonderful to meet IRL! #ACR19 @RheumNow https://t.co/e2tAkkaZZL
Kanika Monga, MD DrKanikaMonga ( View Tweet)
What kind of level of disease control is enough in ANCA-associated vasculitis?
If you can get prolonged remission (BVAS=0 and PNL≥5mg/d for >2y) then you do better than even prolonged low disease activity. Something to target!
French Vasculitis Group #ACR19 ABST1684 @RheumNow https://t.co/L74kZOr9B3
David Liew drdavidliew ( View Tweet)
Certolizunab MRI study showed fewer inflammatory and structural lesions after 4y RX vs Placebo @RheumNow #ACR19 https://t.co/KgeVrPzvPy
Dr. Arthur Lau ArthurRheum ( View Tweet)
#acr19 @rheumnow Draft ACR guidelines for Takayasu:
1. Use noninvasive imaging over cath based imaging
2. Use high dose GCs
3. use DMARD with GCs (MTX, AZP, LEF, MMF)
4. With refractory dz, add TNFi (NOT TCZ!)
5. Monitor dz q3-12 months if in remission
k dao KDAO2011 ( View Tweet)
Therapeutic gaming (non-immersive environment)
Setting & games designed to meet the patient’s goal
Patients enter a state of flow & get engaged
#ACR19 @rheumnow 4M031 https://t.co/oJ7Ynz0Vvt
Dr Irwin Lim _connectedcare ( View Tweet)
MAS is a IFNg driven disease. Upstream IL-1 family members IL-18 and IL-33 are important treatment targets in MAS. Behrens E #ACR19 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
Great question from the audience -> need to be very cautious about thromboembolic issues if thinking about using JAK inhibitors in #lupus #ACR19 @RheumNow Dorner
Philip Robinson philipcrobinson ( View Tweet)